Introduction:

Tirzepatide, a dual GIP and GLP-1 receptor agonist approved in India since July 2024, has shown promising glycemic control and weight loss benefits. This study evaluated effects of six-months therapy with Tirzepatide on Body Mass Index (BMI), HbA1c, and waist circumference (WC) in Indian T2DM patients and explored correlations with changes in these parameters and treatment dose and liver enzymes thus assessing the effect of therapy in improving metabolic health. 

Methods:

• Design: Baseline and six-month follow-up data were collected
• Study Population: Participants taking tirzepatide therapy 
• Outcomes assessed:
  1. BMI
  2. HbA1c
  3. WC
• Statistical analysis: Paired t-tests for changes; correlation analyses for relationships with treatment dose and liver enzymes (SGOT, SGPT)

Results:

1. Significant reductions observed:
   1. BMI: −10.90 ± 3.45 kg/m² (p<0.001)
   2. HbA1c: −1.48 ± 0.87% (p<0.001)
   3. WC: −8.15 ± 3.20 cm (p<0.01)
2. Correlations:
   1. BMI reduction vs HbA1c reduction: r = 0.51 (p=0.002)
   2. Treatment dose vs BMI reduction: r = 0.43 (p=0.015)
   3. Treatment dose vs HbA1c reduction: r = 0.47 (p=0.010)
3. Liver enzymes: SGOT and SGPT trends indicated possible metabolic associations.

Conclusion:

Tirzepatide treatment led to significant improvements in BMI, HbA1c, and WC in Indian T2DM patients, with dose-dependent effects and correlations with metabolic changes. Further studies in larger cohorts are needed to validate these results and the potential of this intervention to improve metabolic health. 

ADA 2025, 20-23 June, Chicago